|本期目录/Table of Contents|

[1]赵忠治,王金淼,魏颖,等.术前外周血NLR与PLR对胃癌预后的评估价值[J].天津医科大学学报,2018,24(01):50-54.
 ZHAO Zhong-zhi,WANG Jin-miao,WEI Ying,et al.Evaluation value?of preoperative peripheral blood NLR and PLR? on prognosis of? gastric cancer[J].Journal of Tianjin Medical University,2018,24(01):50-54.
点击复制

术前外周血NLR与PLR对胃癌预后的评估价值(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24卷
期数:
2018年01期
页码:
50-54
栏目:
临床医学
出版日期:
2018-01-20

文章信息/Info

Title:
Evaluation value?of preoperative peripheral blood NLR and PLR? on prognosis of? gastric cancer
文章编号:
1006-8147(2018)01-0050-05
作者:
赵忠治王金淼魏颖戚 峰
(天津医科大学总医院普通外科,天津 300052)
Author(s):
ZHAO Zhong-zhiWANG Jin-miaoWEI YingQI Feng
(Department of General Surgery, General Hospital,Tianjin Medical University,Tianjin 300052,China)
关键词:
胃癌中性粒细胞与淋巴细胞计数比值血小板与淋巴细胞计数比值预后
Keywords:
gastric cancer neutrophil /lymphocyte ratioplatelet/lymphocyte ratioprognosis
分类号:
R604
DOI:
-
文献标志码:
A
摘要:
目的:探讨术前外周血中性粒细胞与淋巴细胞计数比值(NLR)和血小板与淋巴细胞计数比值(PLR)对胃癌预后的评估价值。方法:收集154例具有完整临床病理资料的胃癌患者,采用ROC曲线分析cutoff值,X2检验、U检验比较不同分组之间的差异,Kaplan-Meier法计算生存率,COX回归模型多因素分析影响患者预后独立风险因素。结果:随访154位患者中失访患者12位,纳入生存分析的患者共142位,其中1年、3年、5年生存率分别为75%、49%、32%。单因素分析示:肿瘤大小(P=0.025)、分化类型(P=0.021)、浸润深度(P=0.007)、淋巴结分期(P<0.001)、淋巴结转移率(P<0.001)、TNM分期(P<0.001)、PLR(P<0.001)、NLR(P<0.001)、手术方式(P=0.013)为影响胃癌患者预后的危险因素;多因素分析示:淋巴结转移率(P=0.004)、TNM分期(P=0.005)、PLR(P=0.001)可能为影响胃癌预后的独立危险因素。结论:PLR、NLR可以用来评价患者预后,PLR可能为影响预后总生存率的独立危险因素。
Abstract:
Objective To examinewhetherneutrophil /lymphocyte ratio (NLR) andplatelet/lymphocyte ratio(PLR) have prognostic value in preoperative peripheral blood of patients undergoing gastric cancer resection. Methods One hundred and fifty-four gastric cancer patients with complete clinical and pathological data were reviewed.The cutoff values ??were analyzed by ROC curve.The differences between groups were compared using chi-square test and U test. The Kaplan-Meier method was used to calculate the survival rate. The COX regression model was applied to analyze the independent prognostic risk factors, which may affect the survival rate.Results One hundred and forty-two cases were followed up.The 1-year, 3-year and 5-year survival rates were 75%, 49% and 32%, respectively. Tumor size (P = 0.025), tumor differentiation type (P = 0.021), depth of tumor invasion (P = 0.007), lymph node staging (P<0.001), lymph node metastasis rate (P<0.001), TNM staging (P<0.001), PLR (P<0.001),NLR (P<0.001) and surgical approach (P = 0.013) were significantly correlated with survival rate by univariate analysis. Multivariate analysis showed that lymph node metastasis rate (P = 0.004), TNM staging (P = 0.005), PLR (P = 0.001) could be independent risks factor for the prognosis of gastric cancer. Conclusion: PLR and NLR can be used to evaluate the prognosis of patients. PLR may be an independent risk factor for the overall survival rate.

参考文献/References:

[1]Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359

[2]Pedrazzani C, Mantovani G, Fernandes E, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer[J]. Sci Rep, 2017, 7(1): 1494

[3]Templeton A J, Mcnamara M G, ?eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014, 106(6): dju124

[4]Zhao Weiwei, Wu Zhenyu, Li Yintao, et al. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic changes are associated with the overall survival in advanced cancer patients undergoing palliative care[J]. Sci Rep, 2016, 6(1): 31394

[5]Caronni N, Savino B, Bonecchi R. Myeloid cells in cancer-related inflammation[J]. Immunobiology, 2015, 220(2): 249

[6]Guthrie G J, Charles K A, Roxburgh C S, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer[J]. Crit Rev OncolHematol, 2013, 88(1): 218

[7]Lee Y, Kim S H, Han J Y, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy[J]. J Cancer Res ClinOncol, 2012, 138(12): 2009

[8]Michael G, ALEXANDRAKIS, Freda H, et al. Levels of serum cytokines and acute phase proteins in patients with essential and Cancer-Related thrombocytosis[J]. Am J ClinOncol(CCT), 2003, 26(2): 135

[9]You J, Zhang H X, Shen Y Y, et al. Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients[J]. Onco Targets Ther, 2017, 10: 2199

[10]Wang J, Qu J L, Li Z, et al. Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer[J]. J Clin Lab Anal, 2017, 10: e22185

[11]Jung M R, Park Y K, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer[J]. J SurgOncol, 2011, 104(5): 504

[12]Shimada H, Takiguchi N, Kainuma Osamu, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer[J]. Gastric Cancer, 2010, 13(3): 170

[13]Pan Q X, Su Z J, Zhang J H, et al. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer[J]. Onco Targets Ther, 2015, 8: 1375

[14]Wang D S, Ren C, Qiu M Z, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer[J]. TumourBiol, 2012, 33(3): 749

[15]Gu X B, Gao X S, Cui M, et al. Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer[J]. Oncotarget, 2016, 7(31): 49878

[16]Sun X W, Liu X C, Liu J J, et al. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer[J]. Chin J Cancer, 2016, 35(1): 57



相似文献/References:

[1]刘新兰,李淑璟,张海霞.候选抑癌基因RASSF6在胃癌组织中的表达及其与临床病理特征的关系[J].天津医科大学学报,2015,21(04):287.
 LIU Xin -lan,LI Shu -jing,ZHANG Hai -xia.Expressions of RASSF6 in gastric cancer and its association with clinicopathologic feature[J].Journal of Tianjin Medical University,2015,21(01):287.
[2]李 静,孙保存,孙 冉,等.环氧合酶2通过上皮间质转换促进胃癌的侵袭与转移 [J].天津医科大学学报,2016,22(03):185.
 LI Jing,SUN Bao-cun,SUN Ran,et al.Cyclooxygenase-2 promotes gastric cancer invasion and metastasis by inducing epithelial to mesenchymal transition[J].Journal of Tianjin Medical University,2016,22(01):185.
[3]郭江涛综述,邓靖宇审校.胃癌淋巴结转移的分子标志物研究进展[J].天津医科大学学报,2017,23(01):85.
[4]张 悦,管叙文,王婧雅,等.miR-27a对胃癌细胞凋亡影响的体外研究[J].天津医科大学学报,2018,24(06):469.
 ZHANG Yue,GUAN Xu-wen,WANG Jing-ya,et al.Influence of miR-27a on apoptosis of gastric cancer cells in vitro[J].Journal of Tianjin Medical University,2018,24(01):469.
[5]白惠惠,邓靖宇,梁 寒.血清肿瘤标志物对胃癌淋巴结转移的诊断价值[J].天津医科大学学报,2019,25(03):241.
 BAI Hui-hui,DENG Jing-yu,LIANG Han.Prognostic value of serum tumor biomarkers for lymph node metastasis of gastric cancer[J].Journal of Tianjin Medical University,2019,25(01):241.
[6]张灿灿,谭志军.FMNL2在胃癌组织中的表达及其临床意义[J].天津医科大学学报,2020,26(02):149.
 ZHANG Can-can,TAN Zhi-jun.Expression and clinical significance of FMNL2 in gastric cancer[J].Journal of Tianjin Medical University,2020,26(01):149.
[7]赵珍珍 综述,邓靖宇 审校.蛋白质组学技术在胃癌研究中的应用[J].天津医科大学学报,2021,27(01):94.
[8]昕宇 综述,邓靖宇,梁寒 审校.主动脉旁淋巴结清扫术在进展期胃癌治疗中的研究进展[J].天津医科大学学报,2021,27(01):99.
[9]左兴盛,宋志玉,贾海盼,等.沉默circPVT1对5-氟尿嘧啶耐药胃癌细胞化疗增敏作用及机制研究[J].天津医科大学学报,2021,27(06):574.
 ZUO Xing-sheng,SONG Zhi-yu,JIA Hai-pan,et al.The sensitizing effect and mechanism of silencing of circPVT1 on 5-fluorouracil chemosensitivity in gastric cancer cells[J].Journal of Tianjin Medical University,2021,27(01):574.
[10]赵路瑶 综述,李慕然,刘艳迪 审校.外周血SEPT9基因甲基化检测在胃癌诊断中的研究进展[J].天津医科大学学报,2022,28(02):218.

备注/Memo

备注/Memo:
作者简介赵忠治(1991-),男,硕士在读,研究方向:外科学(普外);通信作者:戚峰,E-mail: qf@medmail.com.cn

更新日期/Last Update: 2018-01-19